Scott Gottlieb

Guests Steve Witkoff, Trump's former top negotiator, discusses the complexities of Middle East peace talks and the delicate balance in Israel-Hamas negotiations. Former FDA commissioner Scott Gottlieb highlights the urgent public health crises, focusing on alarming measles outbreaks and the need to combat vaccine misinformation. They dive into the repercussions of workforce cuts in health agencies and how these changes could affect American health oversight moving forward. Expect a thought-provoking discussion on governance, health, and international diplomacy.

Scott Gottlieb, former FDA commissioner and healthcare expert, and Patrick Boyle, financial commentator and YouTuber, dive into pressing topics. They explore the political implications of vaccine announcements and transparency issues with big pharma, specifically Pfizer. The conversation shifts to the fintech landscape, discussing the risks of debanking practices and regulatory scrutiny. Gottlieb and Boyle also touch on the geopolitical landscape, with insights into the Ukraine conflict and its broader implications for international relations.

Scott Gottlieb, former head of the FDA and author of 'Uncontrolled Spread,' dives into the lessons learned from the COVID-19 pandemic. He discusses the critical role technology, particularly mRNA vaccine development, played in pandemic response and highlights failures in regulatory translation of science to policy. Joining him are Marc Andreessen, a prominent venture capitalist, and Vineeta Agarwala, a bio expert. They explore the need for improved genomic surveillance, private sector involvement in health infrastructure, and the ethical dilemmas of challenge trials for future preparedness.

Glenn Youngkin, Governor of Virginia and former CEO, discusses the impact of federal policies on Virginia's economy. He expresses optimism despite job losses related to the DOGE phenomenon. Dr. Scott Gottlieb, former FDA Commissioner, highlights concerns over rising costs in the pharmaceutical industry, warning that major medications could face production halts. The discussion also touches on the Trump administration's freeze on $2.2 billion in grants to Harvard, sparking a debate on free speech and government interference in education.

Makan Delrahim, former antitrust assistant attorney general, shares insights on the future of mergers and acquisitions under Trump's administration, emphasizing the cautious strategies businesses are adopting amid regulatory scrutiny. Dr. Scott Gottlieb, former FDA commissioner, discusses the resignation of the FDA's top vaccine official amid rising anti-vaccine sentiments and the U.S. measles outbreak. They highlight the urgent need to restore public trust in health systems and examine the complex interplay between politics and market dynamics.

Scott Gottlieb, former FDA Commissioner and CNBC contributor, dives into the pressing issues of avian flu and its potential threat to America’s food supply, especially rising egg prices. He emphasizes the urgent need for biosecurity measures and the complexities involved in managing the virus among poultry. The conversation also touches on President Trump's executive order to dismantle the Department of Education, highlighting the implications for student oversight and funding. Gottlieb's insights reveal the intersection of public health and economic stability.

Dr. Scott Gottlieb, former FDA commissioner and Pfizer board member, breaks down the complexities of UnitedHealth's Medicare billing amid a DOJ investigation. He discusses healthcare system inefficiencies and the potential impact of bird flu cases. Meanwhile, Brian Armstrong, Coinbase's CEO, shares exciting news about the SEC dropping its lawsuit, emphasizing the need for clear regulations in cryptocurrency. He also touches on meme coins and prediction markets, illuminating the evolving landscape of digital finance.

Amos Hochstein, a former Biden senior advisor, shares insights on the fragile ceasefire in the Israel-Hamas conflict and the urgent humanitarian needs. Dr. Scott Gottlieb, former FDA commissioner, examines the alarming potential impacts of proposed NIH funding cuts on public health research. The conversation also touches on Elon Musk's ambitious $97.4 billion bid for OpenAI and tensions with CEO Sam Altman, and President Trump's pause on anti-bribery law enforcement, raising ethical concerns in international business.

Steve Liesman, a CNBC reporter specializing in economic analysis, discusses the implications of President Trump's tariffs on Canada and Mexico. Former FDA Commissioner Dr. Scott Gottlieb critiques Robert F. Kennedy Jr.'s understanding of healthcare during his challenging confirmation hearings. Mellody Hobson, co-CEO of Ariel Investments, speaks about the exciting investment landscape in women’s sports, particularly with the new National Women’s Soccer League franchise in Denver, advocating for diversity and inclusion in corporate leadership.

Scott Gottlieb, former FDA commissioner, dives into the alarming rise of flu, RSV, and norovirus this winter, shedding light on why these illnesses are peaking. He discusses the strain on healthcare systems and the crucial role of public health policies. Additionally, the conversation touches on major executive changes at Apple and Disney, probing into how these leadership shifts might shape the future of these giants in 2025. The complexities of healthcare challenges and their implications for society also take center stage.